Zai Lab Limited American Depositary Shares ZLAB
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-03T15:43:47.798Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T15:42:54.109349919Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-03T15:35:48.567858+00:00
Zai Lab Limited American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 26.92 | 85.6% | 23.2% | |||
| 25Δ | 25.16 | 75.0% | 15.7% | 20.04 | 82.3% | 12.6% |
| 30Δ | 24.62 | 86.7% | 14.9% | 20.63 | 96.2% | 12.3% |
| 35Δ | 24.20 | 100.5% | 14.8% | 21.23 | 110.1% | 11.9% |
| 40Δ | 23.78 | 114.4% | 14.7% | 21.82 | 124.0% | 11.6% |
| 45Δ | 23.36 | 128.3% | 14.6% | 22.42 | 138.0% | 11.3% |
| 50Δ | 22.94 | 142.1% | 14.5% | 23.84 | 142.7% | 10.3% |
| 55Δ | 22.52 | 156.0% | 14.3% | 25.39 | 146.0% | 9.1% |
| 60Δ | 26.94 | 149.3% | 7.9% | |||
| 65Δ | 28.50 | 152.6% | 6.8% | |||
| 70Δ | 30.05 | 155.9% | 5.6% | |||
| 75Δ | 31.60 | 159.1% | 4.4% | |||
| 80Δ | 19.55 | 73.9% | 2.2% | 33.15 | 162.4% | 3.3% |
20Δ
- Pseudo strike
- 26.92
- IV
- 85.6%
- B/E move
- 23.2%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 25.16
- IV
- 75.0%
- B/E move
- 15.7%
- Pseudo strike
- 20.04
- IV
- 82.3%
- B/E move
- 12.6%
30Δ
- Pseudo strike
- 24.62
- IV
- 86.7%
- B/E move
- 14.9%
- Pseudo strike
- 20.63
- IV
- 96.2%
- B/E move
- 12.3%
35Δ
- Pseudo strike
- 24.20
- IV
- 100.5%
- B/E move
- 14.8%
- Pseudo strike
- 21.23
- IV
- 110.1%
- B/E move
- 11.9%
40Δ
- Pseudo strike
- 23.78
- IV
- 114.4%
- B/E move
- 14.7%
- Pseudo strike
- 21.82
- IV
- 124.0%
- B/E move
- 11.6%
45Δ
- Pseudo strike
- 23.36
- IV
- 128.3%
- B/E move
- 14.6%
- Pseudo strike
- 22.42
- IV
- 138.0%
- B/E move
- 11.3%
50Δ
- Pseudo strike
- 22.94
- IV
- 142.1%
- B/E move
- 14.5%
- Pseudo strike
- 23.84
- IV
- 142.7%
- B/E move
- 10.3%
55Δ
- Pseudo strike
- 22.52
- IV
- 156.0%
- B/E move
- 14.3%
- Pseudo strike
- 25.39
- IV
- 146.0%
- B/E move
- 9.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 26.94
- IV
- 149.3%
- B/E move
- 7.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 28.50
- IV
- 152.6%
- B/E move
- 6.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.05
- IV
- 155.9%
- B/E move
- 5.6%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 31.60
- IV
- 159.1%
- B/E move
- 4.4%
80Δ
- Pseudo strike
- 19.55
- IV
- 73.9%
- B/E move
- 2.2%
- Pseudo strike
- 33.15
- IV
- 162.4%
- B/E move
- 3.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.95% | |
| 74.72% | |
| 75.98% | |
| 80.97% | |
| 68.57% | |
| 64.46% | |
| 73.79% | |
| 78.92% | |
| 70.52% | |
| 79.63% |
Biotechnology
ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers.…
More →ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →